Contrave (naltrexone/bupropion) is a prescription drug used for weight loss and long-term weight management in certain adults. The drug is prescribed along with diet ...

Weight loss medications can be an effective option for people struggling to lose weight through diet and exercise alone. Contrave (naltrexone and bupropion) and Wegovy (semaglutide) are two ...

Contrave and Wegovy are medications prescribed for long-term weight management. Contrave is an oral tablet you take twice daily, and Wegovy is an injectable solution you receive once weekly. Both ...

The study's publication provides important real-world evidence that further substantiates the cardiovascular safety profile of CONTRAVE/MYSIMBA building on findings from prior clinical trials, a ...

The phase 3b IGNITE study shows that naltrexone/bupropion (Contrave/Mysimba, Orexigen) combined with a comprehensive lifestyle intervention led to greater weight loss at 26 weeks than usual care ...

Yet another large-scale study testing the cardiovascular safety of the weight loss combination naltrexone-bupropion has been halted prematurely, TCTMD has confirmed. The trial, known as CONVENE, was ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. The U.S. no longer has the highest obesity rates in the world. It is now second to Mexico, according to a report ...

Contrave can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects last longer than that ...

US physicians treating overweight and obese patients now have four drugs with different mechanisms of action that they can choose to prescribe, to complement diet and exercise. The latest therapeutic ...

Orexigen's failure to keep a lid on a key safety analysis of its obesity drug Contrave led the Food and Drug Administration to force it to do a second study in order to prove that the medicine is safe ...

Forbes contributors publish independent expert analyses and insights. I report the latest in health, nutrition, wellness and healthy travel. Will the FDA finally approve Contrave, Orexigen’s hot new ...

SAN DIEGO, Nov. 25, 2013 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced successful results of the interim analysis of the Light Study. Based on these results, the Company ...